Bibliographic record
Abstract
Canada’s Drug Agency (CDA-AMC) recommends that Imfinzi in combination with Imjudo and platinum-based chemotherapy should be reimbursed by public drug plans for the first-line treatment of adult patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutations or ALK genomic tumour aberrations if certain conditions are met. Imfinzi and Imjudo, in combination with platinum-based chemotherapy should only be covered to treat adult patients with NSCLC who have stage IV NSCLC with tumours that lack sensitizing EGFR mutations or ALK genomic tumour aberrations and have not previously been treated with chemotherapy or other systemic therapy for metastatic disease. Patients must not have untreated or progressive brain metastases. Imfinzi and Imjudo, in combination with platinum-based chemotherapy should only be reimbursed if prescribed by a clinician with expertise and experience in treating NSCLC, and if the cost of Imfinzi and Imjudo, in combination with platinum-based chemotherapy does not exceed the total cost of treatment with the least costly immune checkpoint inhibitors (ICIs) plus a platinum-based chemotherapy regimen reimbursed for the same indication.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.001 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.008 | 0.002 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".